BDNF and NGF Signalling in Early Phases of Psychosis: Relationship with Inflammation and Response to Antipsychotics after 1 Year

Schizophrenia Bulletin

Volumn 42, Issue 1, 2016, Pages 142-151

  Martinez Cengotitabengoa, M ^a,b,c   Macdowell, K S ^b,d   Alberich, S ^a,b   Diaz, F J ^e   Garcia Bueno, B ^b,d   Rodriguez Jimenez, R ^b,f   Bioque, M ^b,g,h   Berrocoso, E ^b,i   Parellada, M ^b,j   Lobo, A ^k   Saiz, P A ^b,l   Matute, C ^m,n   Bernardo, M ^b,g,h   Gonzalez Pinto, A ^a,b,m   Leza, J C ^b,d  

^a HOSPITAL TXAGORRITXU   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ UNIVERSITY OF CÁDIZ   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k UNIVERSITY OF ZARAGOZA   (Spain)

^l UNIVERSITY OF OVIEDO   (Spain)

^m UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

ⁿ CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

more..

Author keywords

antipsychotic; BDNF; first episode psychosis; inflammation; NGF; schizophrenia

Indexed keywords

15-DEOXYPROSTAGLANDIN J2; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOPROTEIN; NERVE GROWTH FACTOR; NEUROLEPTIC AGENT; NGF PROTEIN, HUMAN; NOS2 PROTEIN, HUMAN; PROSTAGLANDIN D2; PROTEIN TYROSINE KINASE A; PTGS2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; FEMALE; HUMAN; IMMUNOLOGY; INFLAMMATION; LONGITUDINAL STUDY; MALE; METABOLISM; MONONUCLEAR CELL; PROGNOSIS; PSYCHOTIC DISORDERS; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MALE; NERVE GROWTH FACTOR; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PROGNOSIS; PROSTAGLANDIN D2; PROTEIN ISOFORMS; PSYCHOTIC DISORDERS; RECEPTOR, TRKA; RECEPTOR, TRKB; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84954348204     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv078     Document Type: Article

References (57)

1. Reardon S. NIH rethinks psychiatry trials. Nature. 2014;507:288.
2. Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull. 2013;39:1174-1179.
3. Feigenson KA, Kusnecov AW, Silverstein SM. Inflammation and the two-hit hypothesis of schizophrenia. Neurosci Biobehav Rev. 2014;38:72-93.
4. Müller N. Immunology of schizophrenia. Neuroimmunomodulation. 2014;21:109-116.
5. Suvisaari J, Mantere O. Inflammation theories in psychotic disorders: A critical review. Infect Disord Drug Targets. 2013;13:59-70.
6. García-Bueno B, Bioque M, Mac-Dowell KS, et al. Pro-/antiinflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull. 2014;40:376-387.
7. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Metaanalysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663-671.
8. Meyer U. Anti-inflammatory signaling in schizophrenia. Brain Behav Immun. 2011;25:1507-1518.
9. Martínez-Gras I, Pérez-Nievas BG, García-Bueno B, et al. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr Res. 2011;128:15-22.
10. Gomes JR, Costa JT, Melo CV, et al. Excitotoxicity downregulates TrkB.FL signaling and upregulates the neuroprotective truncated TrkB receptors in cultured hippocampal and striatal neurons. J Neurosci. 2012;32:4610-4622.
11. Palomino A, Vallejo-Illarramendi A, González-Pinto A, et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res. 2006;86:321-322.
12. Martinotti G, Di Iorio G, Marini S, Ricci V, De Berardis D, Di Giannantonio M. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: A review. J Biol Regul Homeost Agents. 2012;26:347-356.
13. Lykissas MG, Batistatou AK, Charalabopoulos KA, Beris AE. The role of neurotrophins in axonal growth, guidance, and regeneration. Curr Neurovasc Res. 2007;4:143-151.
14. Skaper SD. The neurotrophin family of neurotrophic factors: an overview. Methods Mol Biol. 2012;846:1-12.
15. Carim-Todd L, Bath KG, Fulgenzi G, et al. Endogenous truncated TrkB.T1 receptor regulates neuronal complexity and TrkB kinase receptor function in vivo. J Neurosci. 2009;29:678-685.
16. Ohira K, Shimizu K, Hayashi M. Change of expression of fulllength and truncated TrkBs in the developing monkey central nervous system. Brain Res Dev Brain Res. 1999;112:21-29.
17. Vidaurre OG, Gascón S, Deogracias R, et al. Imbalance of neurotrophin receptor isoforms TrkB-FL/TrkB-T1 induces neuronal death in excitotoxicity. Cell Death Dis. 2012;3:e256.
18. Wong J, Rothmond DA, Webster MJ, Weickert CS. Increases in two truncated TrkB isoforms in the prefrontal cortex of people with schizophrenia. Schizophr Bull. 2013;39:130-140.
19. Yu T, Calvo L, Anta B, et al. Regulation of trafficking of activated TrkA is critical for NGF-mediated functions. Traffic. 2011;12:521-534.
20. Mondelli V, Cattaneo A, Belvederi Murri M, et al. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: A pathway to smaller hippocampal volume. J Clin Psychiatry. 2011;72:1677-1684.
21. Soontornniyomkij B, Everall IP, Chana G, Tsuang MT, Achim CL, Soontornniyomkij V. Tyrosine kinase B protein expression is reduced in the cerebellum of patients with bipolar disorder. J Affect Disord. 2011;133:646-654.
22. Weickert CS, Ligons DL, Romanczyk T, et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry. 2005;10:637-650.
23. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: A systematic review with meta-analysis. Mol Psychiatry. 2011;16:960-972.
24. Pillai A. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals. 2008;16:183-193.
25. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
26. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766-771.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R), Text Revision. 3rd ed. Washington, DC: American Psychiatric Association; 1987.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV, 4th ed. Washington, DC: American Psychiatric Association; 1994.
29. American Psychiatric Association. DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), Text Revision. 4th ed. Washington, DC: American Psychiatric Association; 2000.
30. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: A systematic review with meta-analysis. Mol Psychiatry. 2011;16:960-972.
31. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci. 2010;64:341-357.
32. Klein AB, Williamson R, Santini MA, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011;14:347-353.
33. Harris LW, Pietsch S, Cheng TM, Schwarz E, Guest PC, Bahn S. Comparison of peripheral and central schizophrenia biomarker profiles. PLoS One. 2012;7:e46368.
34. Rollins B, Martin MV, Morgan L, Vawter MP. Analysis of whole genome biomarker expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:919-936.
35. Favalli G, Li J, Belmonte-de-Abreu P, Wong AH, Daskalakis ZJ. The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res. 2012;46:1-11.
36. Fernandes BS, Steiner J, Berk M, et al. Peripheral brainderived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications [published online ahead of print September 30, 2014]. Mol Psychiatry. doi:10.1038/mp.2014.117.
37. Lee BH, Kim YK. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. Neuropsychobiology. 2009;59:51-58.
38. Yi Z, Zhang C, Wu Z, et al. Lack of effect of brain derived neurotrophic factor (BDNF) Val66Met polymorphism on early onset schizophrenia in Chinese Han population. Brain Res. 2011;1417:146-150.
39. Vyas NS, Puri BK. Evidence for an association between brain-derived neurotrophic factor Val66Met gene polymorphism and general intellectual ability in early-onset schizophrenia. Isr J Psychiatry Relat Sci. 2012;49:137-142.
40. Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res. 2003;60:117-123.
41. Xiong P, Zeng Y, Zhu Z, et al. Reduced NGF serum levels and abnormal P300 event-related potential in first episode schizophrenia. Schizophr Res. 2010;119:34-39.
42. Xiong P, Zeng Y, Wan J, et al. The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia. Psychiatry Res. 2011;189:72-76.
43. Pandya CD, Kutiyanawalla A, Pillai A. BDNF-TrkB signaling and neuroprotection in schizophrenia. Asian J Psychiatr. 2013;6:22-28.
44. Mackin P, Gallagher P, Watson S, Young AH, Ferrier IN. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust N Z J Psychiatry. 2007;41:321-326.
45. Kim SW, Cho KJ. Activity-dependent alterations in the sensitivity to BDNF-TrkB signaling may promote excessive dendritic arborization and spinogenesis in fragile X syndrome in order to compensate for compromised postsynaptic activity. Med Hypotheses. 2014;83:429-435.
46. Faria MC, Gonçalves GS, Rocha NP, et al. Increased plasma levels of BDNF and inflammatory markers in Alzheimer's disease. J Psychiatr Res. 2014;53:166-172.
47. Charoenphandhu N, Nuntapornsak A, Wongdee K, Krishnamra N, Charoenphandhu J. Upregulated mRNA levels of SERT, NET, MAOB, and BDNF in various brain regions of ovariectomized rats exposed to chronic aversive stimuli. Mol Cell Biochem. 2013;375:49-58.
48. González-Pinto A, Mosquera F, Palomino A, et al. Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics. Int Clin Psychopharmacol. 2010;25:241-245.
49. Luoni A, Berry A, Calabrese F, et al. Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence. Eur Neuropsychopharmacol. 2014;24:986-995.
50. Pedrini M, Chendo I, Grande I, et al. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: A positive correlation. Neurosci Lett. 2011;491:207-210.
51. Pirildar S, Gönül AS, Taneli F, Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:709-713.
52. Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry. 2010;11:256-261.
53. Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett. 2005;382:27-32.
54. Kapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry. 2012;17:1174-1179.
55. Ricci V, Martinotti G, Gelfo F, et al. Chronic ketamine use increases serum levels of brain-derived neurotrophic factor. Psychopharmacology (Berl). 2011;215:143-148.
56. Angelucci F, Ricci V, Martinotti G, et al. Ecstasy (MDMA)-addicted subjects show increased serum levels of brain-derived neurotrophic factor, independently from a rise of druginduced psychotic symptoms. Addict Biol. 2010;15:365-367.
57. Angelucci F, Ricci V, Gelfo F, et al. BDNF serum levels in subjects developing or not post-traumatic stress disorder after trauma exposure. Brain Cogn. 2014;84:118-122.